

# Influenza vaccination as a prognostic factor of humoral IgA responses to SARS-CoV-2 infection

BARBARA PONIEDZIAŁEK<sup>1</sup>, DOMINIKA SIKORA<sup>2</sup>, EWELINA HALLMANN<sup>3</sup>, LIDIA BRYDAK<sup>3</sup>, PIOTR RZYMSKI<sup>1</sup>

<sup>1</sup>Department of Environmental Medicine, Poznan University of Medical Sciences, Poznań, Poland

<sup>2</sup>Doctoral School, Poznan University of Medical Sciences, Poznań, Poland

<sup>3</sup>Laboratory of Influenza Viruses and Respiratory Infection Viruses, Department of Virology at the National Institute of Public Health NIH – National Research Institute in Warsaw, Poland

## Abstract

There is evidence that influenza vaccination may provide additional benefits by inducing training of innate immunity and increasing humoral responses to heterologous challenges. Immunoglobulin A (IgA) antibodies dominate the early phase of the adaptive response to SARS-CoV-2 infection, but whether their production may be associated with previous influenza vaccination has not been a subject of any study. This study compared serum SARS-CoV-2-specific IgA responses, measured with Microblot-Array assay, in individuals who experienced COVID-19 ( $N = 1318$ ) and differed in the status of the seasonal influenza vaccine, age, sex, and disease severity. Influenza-vaccinated individuals had a higher seroprevalence of IgA antibodies against nucleocapsid (anti-NP; by 10.1%), receptor-binding domain of spike protein (anti-RBD; by 11.8%) and the S2 subunit of spike protein (anti-S2; by 6.8%). Multivariate analysis, including age, sex, and COVID-19 severity, confirmed that receiving the influenza vaccine was associated with higher odds of being seropositive for anti-NP (OR, 95% CI = 1.57, 1.2-2.0), anti-RBD (OR, 95% CI = 1.6, 1.3-2.0), and anti-S2 (OR, 95% CI = 1.9, 1.4-2.7), as well as being seropositive for at least one anti-SARS-CoV-2 IgA antibody (OR, 95% CI = 1.7, 1.3-2.1) and all three of them (OR, 95% CI = 2.6, 1.7-4.0). Age  $\geq 50$  years was an additional factor predicting better IgA responses. However, the concentration of particular antibodies in seropositive subjects did not differ in relation to the influenza vaccination status. The study evidenced that influenza vaccination was associated with improved serum IgA levels produced in response to SARS-CoV-2 infection. Further studies are necessary to assess whether trained immunity is involved in the observed phenomenon.

**Key words:** heterologous protection, trained immunity, adaptive immunity, immunology, SARS-CoV-2, pandemic.

(Cent Eur J Immunol 2024; 49 (1): 11-18)

## Introduction

The adaptive response to viral infections, which includes both B-cell-based humoral immunity and T-cell-based cellular immunity, can be influenced by various factors, including age, sex, disease severity, comorbidities, and medicines. For example, it is more frequently deteriorated in elderly individuals due to immunosenescence [1], males due to different effects of sex hormones on the immune system [2], and immunosuppressed patients [3], while asymptomatic or mildly infected subjects may mount different humoral and cellular adaptive responses than those who are severely or critically ill [4].

There is also some recent evidence that influenza vaccination may increase the strength of the adaptive response to other viral infections. As demonstrated, receiving concomitant pneumococcal and influenza or only influenza vaccine resulted in a higher concentration of antibodies against the SARS-CoV-2 receptor binding domain (RBD) and increased micro-neutralization titers following administration of COVID-19 mRNA vaccine [5, 6]. Moreover, COVID-19 convalescent patients who previously received seasonal influenza vaccination were characterized by higher seroprevalence and concentrations of immunoglobulin (Ig) G antibodies against RBD and nucleocapsid protein [7]. The exact mechanisms behind such an effect remain to be elucidated.

Correspondence: Prof. Piotr Rzymiski, Department of Environmental Medicine, Poznan University of Medical Sciences, Poznań, Poland, e-mail: [rzymkipiotr@ump.edu.pl](mailto:rzymkipiotr@ump.edu.pl)  
Submitted: 05.11.2023, Accepted: 18.01.2024

However, it is hypothesized that it may arise from vaccination-driven interleukin (IL)-4 production by T-helper 2 cells that leads to improved clonal expansion of B cells as well as elevated IL-5 and IL-6 production, which play a role in the later phase of B-cell activation by supporting their differentiation and antibody production [7, 8]. Moreover, it is suggested that influenza vaccination can induce innate immune training in myeloid cells by altering cytokine production through epigenetic reprogramming of transcriptional pathways, ultimately leading to better support of adaptive humoral responses [9-11]. Various observations indicate that such trained immunity may exist in the context of the influenza vaccine. Individuals who received seasonal vaccination were characterized by lower exposure to seasonal alphacoronaviruses and decreased risk of SARS-CoV-2 infection, hospitalization, need for mechanical ventilation, and death due to COVID-19 [12-15].

If one considers that influenza vaccination improves heterologous adaptive humoral responses to SARS-CoV-2, this effect is likely to occur not only in relation to the production of IgG antibodies, which are generated later, but also immunoglobulins produced in the earlier phases. It is evidenced that contrary to various other viral infections, IgA antibodies, instead of IgM, dominate the early phase of the humoral response to SARS-CoV-2 due to their preferential expression by circulating plasmablasts [16, 17].

Therefore, the present study compared SARS-CoV-2-specific IgA responses in a large group of COVID-19 convalescents who were not vaccinated against COVID-19 but had a primary SARS-CoV-2 infection and differed in the status of the seasonal influenza vaccine. This is the first study to explore the potential association between influenza vaccination and humoral responses to SARS-CoV-2 infection in relation to this antibody class, which, contrary to IgG and IgM studies, was often not included in the serosurveillance investigations conducted in the early phases of the COVID-19 pandemic.

## Material and methods

### Collection of serum samples

All serum samples for this study were purchased in 2020 from Regional Blood Donation and Blood Treatment Centers located across Poland in nine voivodeships (Greater Poland, Kuyavia-Pomerania, Lesser Poland, Lower Silesia, Łódź, Masovian, Podlaskie, Silesia, Western Pomerania), according to accepted safeguard standards and legal requirements. All samples were collected between September and December 2020 from individuals with a history of SARS-CoV-2 infection confirmed with RT-PCR and one month after the resolution of COVID-19 symptoms/end of the isolation period. This period was dominated by infections with Nextstrain clades 20A, 20B, and 20C [18], which did not show significant differences in clinical out-

comes [19, 20]. Until the end of 2020, 1.2 million SARS-CoV-2 infections were confirmed in Poland; the majority of these (approx. 95%) were detected in September-December 2020 [21]. Therefore, it can be assumed that most, if not all, studied individuals experienced primary SARS-CoV-2 infection, particularly if one considers that this period was characterized by various social distancing and isolation measures and a low level of reinfections [22].

In total, 1318 serum samples were purchased, of which 659 were collected from individuals vaccinated against influenza during the 2019/2020 epidemic season and 659 from unvaccinated persons. All influenza-vaccinated individuals received the vaccine in the recommended period between September and December 2019, approximately one year prior to confirmed infection with SARS-CoV-2. An inactivated quadrivalent influenza vaccine used in the 2019/2020 season in the Northern Hemisphere consisted of the following antigens: (i) an A/Brisbane/02/2018 (H1N1)pdm09-like virus, (ii) an A/Kansas/14/2017 (H3N2)-like virus, (iii) a B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage), and (iv) a B/Phuket/3073/2013-like virus [23]. The data regarding age, sex, and severity of SARS-CoV-2 infection in studied individuals were gathered by the Regional Blood Donation and Blood Center. Patients who reported not having any symptoms of infection were classified as asymptomatic, those who were symptomatic but did not require hospitalization were considered to have mild disease, and cases of patients whose symptoms required hospitalization were defined as severe. All studied individuals experienced primary SARS-CoV-2 infection. None of the studied individuals were vaccinated against COVID-19 since the samples were collected in the last quarter of 2020 because the vaccines had not yet been authorized.

The study was conducted in accordance with the Declaration of Helsinki and approved by the Bioethical Committee of the Institute of Public Health – National Research Institute (protocol code 4/2020, 6 August 2020) and the Bioethics Committee at the Poznan University of Medical Sciences (protocol code 429/22, 11 May 2022).

### Determination of anti-SARS-CoV-2

#### IgA antibodies

The prevalence and concentration of three anti-SARS-CoV-2 IgA antibodies were determined in the present study: IgA against nucleocapsid protein (anti-NP), receptor-binding domain of the spike protein (anti-RBD), and subunit S2 of the spike protein (anti-S2). All antibodies were determined using the CE-IVD certified Microblot-Array COVID-19 IgA Assay (TestLine Clinical Diagnostics). In this assay, recombinant and purified native antigens are immobilized on specific spots of nitrocellulose membrane fixed at the bottom of the microplate well [24]. The concentrations for all three IgA antibodies were given as U/ml and interpreted as positive if > 210 U/ml.

**Table 1.** Main characteristics of the studied group

Parameter	All individuals (N = 1318)	Influenza vaccinated (n = 659)	Influenza unvaccinated (n = 659)	p-value
Age, mean ±SD (min-max)	37.2 ±9.8 (18-83)	37.7 ±9.9 (18-83)	36.7 ±9.6 (18-63)	0.08 <sup>a</sup>
< 50 years, % (n)	88.8 (1170)	88.2 (581)	89.4 (589)	0.47 <sup>b</sup>
≥ 50 years, % (n)	11.2 (148)	11.8 (78)	10.6 (70)	
Gender, % (n)				
Male	79.7 (1050)	76.0 (501)	83.3 (549)	0.001 <sup>b</sup>
Female	20.3 (268)	24.0 (158)	16.7 (110)	
COVID-19 severity, % (n)				
Asymptomatic	28.0 (369)	17.3 (114)	38.7 (255)	< 0.001 <sup>b</sup>
Mild	69.8 (919)	80.3 (529)	59.3 (391)	
Severe	2.2 (29)	2.4 (16)	2.0 (13)	

<sup>a</sup> refers to Mann-Whitney U test, <sup>b</sup> refers to Pearson's chi-square test

**Statistical analyses**

The statistical analyses were performed using Statistica v.13.1 (StatSoft) and MedCalc 15.8 (MedCalc Software). The differences in the seroprevalence of antibodies against SARS-CoV-2 between particular sub-groups were analyzed with Pearson's chi-square test. Differences in antibody concentrations were assessed with the non-parametric Mann-Whitney U test (comparison of two groups) or Kruskal-Wallis ANOVA (comparison of three groups) since data did not meet the assumption of Gaussian distribution. Multiple logistic regression models were employed to evaluate the association between seropositivity and patients' characteristics, including age, sex, COVID-19 severity, and influenza vaccination status. A p-value below 0.05 was deemed statistically significant.

**Results**

**Characteristics of studied patients**

The characteristics of the studied individuals are summarized in Table 1. Most of them were less than 50 years old and male and experienced mild COVID-19. There was no difference in age between influenza-vaccinated and unvaccinated groups, although the former had a higher percentage of females and individuals with mild COVID-19 (Table 1).

**Seroprevalence and concentration of anti-SARS-CoV-2 IgA antibodies**

The overall seroprevalence of anti-NP, anti-RBD, and anti-S2 IgA antibodies in the studied group was 32.5%, 58.9%, and 14.3%, respectively. The majority (67.2%) had produced at least one anti-SARS-CoV-2 IgA antibody, but only 8.3% produced all three. As shown in Table 2, seroprevalence differed among the various subgroups. Indi-

**Table 2.** Seroprevalence (%) of anti-SARS-CoV-2 IgA antibodies in relation to characteristics of the studied group (N = 1318)

Parameter	anti-NP	anti-RBD	anti-S2
Age			
< 50 years	31.2	57.5	14.6
≥ 50 years	43.2	66.6	16.2
p	0.003	0.005	0.61
Gender			
Male	31.5	57.4	14.2
Female	36.6	64.6	14.6
p	0.12	0.03	0.88
COVID-19 severity			
Asymptomatic	30.6	38.2	13.6
Mild	32.8	42.7	13.6
Severe	51.7	31.0	44.8
p	0.04	0.18	< 0.0001
Influenza vaccination status			
Yes	37.6	64.8	18.2
No	27.5	53.0	11.4
p	< 0.0001	< 0.0001	0.0005

viduals ≥ 50 years had a higher seroprevalence of anti-NP and anti-RBD, and women produced anti-RBD more frequently, while subjects who were recovering from severe COVID-19 had the highest prevalence of anti-NP and anti-S2 antibodies. Influenza vaccination status was the only factor associated with seroprevalence of all three anti-SARS-CoV-2 IgA antibodies, higher levels of which were observed in individuals vaccinated against influenza in the 2019/2020 epidemic season (Table 2). Moreover,

**Table 3.** Seroprevalence (%) of at least one anti-SARS-CoV-2 IgA antibody and all three determined antibodies (anti-NP, anti-RBD, and anti-S2) in relation to characteristics of the studied group (N = 1318)

Parameter	At least one IgA antibody	Three IgA antibodies
Age		
< 50 years	74.4	12.8
≥ 50 years	66.0	7.7
<i>p</i>	0.01	0.03
Gender		
Male	65.6	8.2
Female	73.1	8.6
<i>p</i>	0.02	0.84
COVID-19 severity		
Asymptomatic	66.9	7.9
Mild	66.7	7.6
Severe	82.8	34.5
<i>p</i>	0.02	< 0.0001
Influenza vaccination status		
Yes	73.0	11.7
No	61.3	4.9
<i>p</i>	0.00001	0.00001


vaccinated individuals were more frequently positive for at least one and all three IgA antibodies, similarly to those who had severe COVID-19 or were aged over 50 years (Table 3).

Because age, gender, COVID-19 severity, and influenza vaccination status differentiated the seroprevalence of anti-SARS-CoV-2 IgA antibodies, all of them were included in the multivariate analysis. Being vaccinated against influenza in the 2019/2020 infection season was associated with higher odds of seropositivity of all three IgA antibodies. In addition, individuals aged ≥ 50 years had high odds of anti-NP and anti-RBD seroprevalence, while those who were recovering from severe COVID-19 had higher odds of anti-NP and anti-S2 IgA antibodies (Fig. 1). Influenza vaccination was also associated in multivariate analysis with significantly higher odds of being seropositive for at least one of the considered IgA antibodies as well as being seropositive for all three of them (Fig. 2).

The serum concentrations (mean ±SD) of anti-NP, anti-RBD, and anti-S2 IgA antibodies in the studied cohort were 448 ±219, 437 ±187, and 322 ±119 U/ml. In most cases, they were not differentiated among particular subgroups, except for higher anti-NP noted in individuals aged less than 50 (Table 4).

### Discussion

It is postulated that influenza vaccination, similarly to other vaccines, e.g., Bacillus-Calmette-Guérin (BCG) vaccine or measles, mumps and rubella (MMR) vaccine [25-27], may provide benefits to heterologous viral challenges [14, 28, 29]. These observations mostly concern improved protection against other infections or lower disease severity. The present study shows that such additional benefits of vaccination may also relate to better plasticity of adaptive humoral immunity in response to heterologous infection, i.e., by SARS-CoV-2. Our previous study showed this in relation to IgG antibodies in patients who experienced mild COVID-19 [7], while this study evidences it in rela-




**Fig. 1.** Logistic multiple regression results on the association between seropositivity for IgA antibodies against SARS-CoV-2 nucleocapsid protein (A), receptor-binding domain (B), and S2 subunit of spike protein (C), and characteristics of COVID-19 convalescents (N = 1318). The data are presented as the odds ratio and 95% confidence interval

tion to IgA class and demonstrates that it is independent of the severity of infection, age, and sex.

There is increasing interest in vaccine-induced trained immunity, a phenomenon of long-term reprogramming of innate cells through epigenetic modifications that ultimately enable non-specific protective effects [30]. In line with this, studies have demonstrated that influenza vaccination is associated with transcriptional and functional reprogramming of innate immune cells, leading to changes in the regulation of inflammatory responses, cell signaling, and antigen presentation [9]. One of the most upregulated genes in monocytes is *CTSS*, encoding cathepsin S, a protein fundamental for MHC II maturation, processing and presentation of antigens [31]. A similar protein, cathepsin L, is well known to play a role in endocytic cellular entry of SARS-CoV-2 [32]. However, cathepsin S has been shown to cleave spike protein at G700 and V860 to release 17, 46, and 78 kDa fragments [33]. This suggests that increased monocytic expression of *CTSS* in individuals vaccinated against influenza could represent one of the pathways of enhanced presentation of SARS-CoV-2 antigens, ultimately stimulating better and broader adaptive humoral responses, including the production of specific IgA antibodies shown to dominate the early phase of the adaptive response to SARS-CoV-2 [16, 17].

Further studies are required to confirm the observations reported in the present research under controlled conditions, e.g., using *in vivo* experimental models with rodents vaccinated against influenza and challenged with SARS-CoV-2. Moreover, broad screening of the epigenetic modifications in isolated populations of immune cells before and after influenza vaccination in animals and humans would enable a better understanding of how it could stimulate heterologous responses of adaptive immunity. These studies are necessary to directly assess whether trained immunity is involved in the phenomenon observed in the present study and, if so, through which pathways. Last but not least, it is of interest to explore whether a similar association as reported in the present study could also occur in relation to other viral infections, e.g., respiratory syncytial virus.

Studies examining humoral responses following COVID-19 vaccination indicate that serum anti-RBD IgA antibodies confer protection against SARS-CoV-2 infection [34]. However, infection-induced IgA antibodies may provide even more potent protection as they can recognize epitopes beyond the spike antigen, e.g., associated with nucleocapsid protein. In line with this, systemic IgA antibodies in COVID-19 were found to contribute to viral neutralization [35] and protect against infection [36]. Therefore, increased IgA seroprevalence associated in the present study with seasonal influenza vaccination may contribute to decreased COVID-19 burden related to reinfections. It would also be interesting to explore whether influenza



**Fig. 2.** Logistic multiple regression results on the association between seropositivity for at least one IgA antibody and all three determined IgA antibodies against SARS-CoV-2 (anti-NP, anti-RBD, and anti-S2), and characteristics of COVID-19 convalescents ( $N = 1318$ ). The data are presented as the odds ratio and 95% confidence interval

**Table 4.** Serum concentrations of anti-SARS-CoV-2 IgA antibodies (U/ml) in relation to characteristics of the studied group ( $N = 1318$ ). The data are presented as mean  $\pm$  SD

Parameter	anti-NP	anti-RBD	anti-S2
<b>Age</b>			
< 50 years	458 $\pm$ 220	442 $\pm$ 168	317 $\pm$ 116
$\geq$ 50 years	397 $\pm$ 203	405 $\pm$ 168	362 $\pm$ 134
<i>p</i>	0.02	0.06	0.11
<b>Gender</b>			
Male	449 $\pm$ 218	434 $\pm$ 186	322 $\pm$ 120
Female	444 $\pm$ 224	447 $\pm$ 191	322 $\pm$ 118
<i>p</i>	0.57	0.32	0.88
<b>COVID-19 severity</b>			
Asymptomatic	469 $\pm$ 231	448 $\pm$ 193	298 $\pm$ 88
Mild	441 $\pm$ 214	432 $\pm$ 184	324 $\pm$ 122
Severe	424 $\pm$ 215	450 $\pm$ 221	393 $\pm$ 165
<i>p</i>	0.64	0.60	0.11
<b>Influenza vaccination status</b>			
Yes	453 $\pm$ 218	431 $\pm$ 186	323 $\pm$ 126
No	442 $\pm$ 220	445 $\pm$ 189	321 $\pm$ 106
<i>p</i>	0.25	0.28	0.34

vaccination is associated with improved production of circulating IgA antibodies against SARS-CoV-2 induced in response to COVID-19 vaccination.

Besides the association of influenza vaccination with a better humoral response, an important observation from the present study is that 33% of studied COVID-19 convalescents had no detectable serum levels of any of the investigated anti-SARS-CoV-2 IgA antibodies, 77.5% were neg-

ative for anti-NP, 41% for anti-RBD, and 86% for anti-S2. Analyses of anti-SARS-CoV-2 IgG antibodies conducted within a similar period after infection reported much higher seroprevalence [7, 37, 38]. Although concentrations of serum IgA levels tend to diminish faster than the IgG response, the results of previous studies indicate they should not fall below detection limits within one month after infection in seroconverted individuals [17, 39, 40].

Some studies have indicated that IgA responses during SARS-CoV-2 positively correlate with disease severity, although there is no consensus in this regard [17, 39, 41]. The findings of the present research support this indication, since the highest and broadest seroprevalence of IgA antibodies was found in individuals who were recovering from severe COVID-19. However, their concentrations did not differ from those found in mildly or asymptotically infected patients. Although females frequently mount better humoral responses than men, including in the context of COVID-19 [42, 43], multivariate analysis performed in the present study did not indicate that it affects the prevalence of anti-SARS-CoV-2 IgA antibodies, for which gender differences were not explored previously. Interestingly, the odds of seropositivity for anti-NP and anti-RBD were also higher in subjects aged 50 and over. Older individuals may have a diminished adaptive immune response and frequently produce lower antibody titers after immunization [44-46]. However, studies conducted in the context of COVID-19 have rarely explored the potential age-dependent differences in IgA production [39]. Nevertheless, research conducted before the COVID-19 pandemic indicated that serum IgA responses are maintained despite aging and may even be enhanced, as some older individuals had higher IgA titers [47-49]. The present study confirms that compared to younger subjects, IgA plays a more significant role in adaptive humoral immunity to SARS-CoV-2 in those aged  $\geq 50$ , suggesting the need for more frequent determinations of these antibodies in COVID-19 serological surveys conducted across different age groups.

Strengths of our study include analyzing a relatively large number of serum samples collected in a narrow timeframe from influenza-vaccinated and influenza-unvaccinated individuals after primary exposure to SARS-CoV-2 antigen without a history of COVID-19 vaccination. Moreover, the present study provides valuable data on the seroprevalence of IgA antibodies in Polish individuals infected with SARS-CoV-2 in the early pandemic phase, which, contrary to IgM or IgG antibodies, were not investigated in previous research focusing on patients undergoing infection in 2020 [50, 51]. Study limitations should also be stressed. Firstly, it was not designed to explore whether increased seroprevalence of IgA antibodies associated with influenza vaccination or other parameters translated into improved protection against reinfection or less severe

reinfections. As long as such an effect may occur, it would require direct research that at present is lacking. Secondly, the analyzed serum samples were collected prior to the emergence and domination of SARS-CoV-2 variants of concern, including the highly transmissible Omicron lineage, and from individuals vaccinated against influenza in the 2019/2020 epidemic season. Therefore, generalizing the phenomenon reported in the present study should be done cautiously until novel data become available. Thirdly, due to the unavailability of information, the study did not include selected variables that could also influence humoral responses, e.g., using immunosuppressive agents (prior to and during the SARS-CoV-2 infection) and other medications, specific comorbidities, nutritional status, or body mass index. Lastly, serum IgA concentrations determined in the present study do not necessarily correlate with their secretory counterparts, as the local immune responses are typically generated independently from systemic IgA. Mucosal IgA antibodies play a major role in neutralizing respiratory viruses at their entry site; therefore, it would be interesting to determine whether influenza vaccination might also be associated with better heterologous responses at the mucosal site. However, addressing it in naïve individuals may currently be challenging, since it was expected that by the end of 2023 the vast majority of the world's population would have been exposed (often multiple times) to SARS-CoV-2 antigen(s) through natural infection and/or vaccination [52, 53]. At the same time, it should be noted that the intramuscular inactivated influenza vaccine (received by the individuals included in the present study) primarily elicits circulating antibodies; thus, its effect on heterologous mucosal IgA responses is unlikely.

## Conclusions

The present study provides additional evidence that the benefits of seasonal influenza vaccination may go beyond homologous protection by improving adaptive immune responses to heterologous challenges. As shown, individuals vaccinated against influenza approximately one year prior to SARS-CoV-2 infection had a higher and broader seroprevalence of anti-SARS-CoV-2 IgA antibodies. Further studies are required to elucidate the exact mechanism behind this phenomenon and explore whether it can also occur in the context of adaptive cellular immunity.

## Funding

This research was funded by the National Institute of Public Health NIH, National Research Institute, grant number 1BIBW/2022.

---

*The authors declare no conflict of interest.*

## References

1. Fulton RB, Varga SM (2009): Effects of aging on the adaptive immune response to respiratory virus infections. *Aging Health* 5: 775.
2. Klein SL (2012): Sex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseases. *Bioessays* 34: 1050-1059.
3. Hirzel C, Ferreira VH, L'Huillier AG, et al. (2019): Humoral response to natural influenza infection in solid organ transplant recipients. *Am J Transplant* 19: 2318-2328.
4. Silva MJA, Ribeiro LR, Lima KVB, Lima LNGC (2022): Adaptive immunity to SARS-CoV-2 infection: A systematic review. *Front Immunol* 13: 1001198.
5. Puro V, Castilletti C, Agrati C, et al. (2021): Impact of prior influenza and pneumococcal vaccines on humoral and cellular response to SARS-CoV-2 BNT162b2 vaccination. *Vaccines (Basel)* 9: 615.
6. Greco M, Cucci F, Portulano P, et al. (2021): Effects of influenza vaccination on the response to BNT162b2 messenger RNA COVID-19 vaccine in healthcare workers. *J Clin Med Res* 13: 549-555.
7. Poniedziałek B, Hallmann E, Sikora D, et al. (2022): Relationship between humoral response in COVID-19 and seasonal influenza vaccination. *Vaccines (Basel)* 10: 1621.
8. Janeway CA Jr, Travers P, Walport M, Shlomchik MJ (2001): *B-cell activation by armed helper T cells*. Garland Science, London, England 2001.
9. Debisarun PA, Gössling KL, Bulut O, et al. (2021): Induction of trained immunity by influenza vaccination - impact on COVID-19. *PLoS Pathog* 17: e1009928.
10. Wagstaffe HR, Pickering H, Houghton J, et al. (2019): Influenza vaccination primes human myeloid cell cytokine secretion and NK cell function. *J Immunol* 203: 1609-1618.
11. Geckin B, Konstantin Föhse F, Domínguez-Andrés J, Netea MG (2022): Trained immunity: implications for vaccination. *Curr Opin Immunol* 77: 102190.
12. Conlon A, Ashur C, Washer L, et al. (2021): Impact of the influenza vaccine on COVID-19 infection rates and severity. *Am J Infect Control* 49: 694-700.
13. Wilcox CR, Islam N, Dambha-Miller H (2021): Association between influenza vaccination and hospitalisation or all-cause mortality in people with COVID-19: a retrospective cohort study. *BMJ Open Respir Res* 8: e000857.
14. Su W, Wang H, Sun C, et al. (2022): The association between previous influenza vaccination and COVID-19 infection risk and severity: A systematic review and meta-analysis. *Am J Prev Med* 63: 121-130.
15. Brydak L, Sikora D, Poniedziałek B, et al. (2023): Association between the seroprevalence of antibodies against seasonal alphacoronaviruses and SARS-CoV-2 humoral immune response, COVID-19 severity, and influenza vaccination. *J Clin Med* 12: 1733.
16. Sterlin D, Mathian A, Miyara M, et al. (2021): IgA dominates the early neutralizing antibody response to SARS-CoV-2. *Sci Transl Med* 13: eabd2223.
17. Takamatsu Y, Omata K, Shimizu Y, et al. (2022): SARS-CoV-2-neutralizing humoral IgA response occurs earlier but is modest and diminishes faster than IgG response. *Microbiol Spectr* 10: e0271622.
18. Genomic epidemiology of SARS-CoV-2 with subsampling focused globally since pandemic start [Internet]. Available from: <https://nextstrain.org/ncov/gisaid/global/> (cited 2022 Oct 3).
19. Flisiak R, Rzymiski P, Zarębska-Michaluk D, et al. (2021): Demographic and clinical overview of hospitalized COVID-19 patients during the first 17 months of the pandemic in Poland. *J Clin Med* 11: 117.
20. Hoang VT, Colson P, Levasseur A, et al. (2021): Clinical outcomes in patients infected with different SARS-CoV-2 variants at one hospital during three phases of the COVID-19 epidemic in Marseille, France. *Infect Genet Evol* 95: 105092.
21. Mathieu E, Ritchie H, Rodés-Guirao L, et al. (2020): Coronavirus pandemic (COVID-19). Our World in Data [Internet]. Available from: <https://ourworldindata.org/covid-hospitalizations> (cited 2022 Dec 14).
22. Medić S, Anastassopoulou C, Lozanov-Crvenković Z, et al. (2022): Risk and severity of SARS-CoV-2 reinfections during 2020-2022 in Vojvodina, Serbia: A population-level observational study. *Lancet Reg Health Eur* 20: 100453.
23. WHO. Recommendations on influenza vaccination during the 2019-2020 winter season [Internet] (2019). Available from: [https://www.euro.who.int/\\_\\_data/assets/pdf\\_file/0017/413270/Influenza-vaccine-recommendations-2019-2020\\_en.pdf](https://www.euro.who.int/__data/assets/pdf_file/0017/413270/Influenza-vaccine-recommendations-2019-2020_en.pdf) (cited 2023 Feb 11).
24. Montesinos I, Dahma H, Wolff F, et al. (2021): Neutralizing antibody responses following natural SARS-CoV-2 infection: Dynamics and correlation with commercial serologic tests. *J Clin Virol* 144: 104988.
25. Kovačić D, Gajić AA, Latinović D, Softić A (2021): Hypothetical immunological and immunogenetic model of heterogeneous effects of BCG vaccination in SARS-CoV-2 infections: BCG-induced trained and heterologous immunity. *J Med Sci* 90: e551.
26. Kleinnijenhuis J, Quintin J, Preijers F, et al. (2012): Bacille Calmette-Guérin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. *Proc Natl Acad Sci U S A* 109: 17537-17542.
27. Higgins JPT, Soares-Weiser K, López-López JA, et al. (2017): Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review. *BMJ* 356: j1241.
28. Tayar E, Abdeen S, Abed Alah M, et al. (2023): Effectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar. *J Infect Public Health* 16: 250-256.
29. Kumar D, Ferreira VH, Campbell P, et al. (2017): Heterologous immune responses to influenza vaccine in kidney transplant recipients. *Am J Transplant* 17: 281-286.
30. Netea MG, Domínguez-Andrés J, Barreiro LB, et al. (2020): Defining trained immunity and its role in health and disease. *Nat Rev Immunol* 20: 375-388.
31. Smyth P, Sasiwachirangkul J, Williams R, Scott CJ (2022): Cathepsin S (CTSS) activity in health and disease – A treasure trove of untapped clinical potential. *Mol Aspects Med* 88: 101106.
32. Ou X, Liu Y, Lei X, et al. (2020): Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. *Nat Commun* 11: 1620.
33. Bollavaram K, Leeman TH, Lee MW, et al. (2021): Multiple sites on SARS-CoV-2 spike protein are susceptible to proteolysis by cathepsins B, K, L, S, and V. *Protein Sci* 30: 1131-1143.
34. Sheikh-Mohamed S, Isho B, Chao GYC, et al. (2022): Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection. *Mucosal Immunol* 15: 799-808.

35. Davis SK, Selva KJ, Lopez E, et al. (2022): Heterologous SARS-CoV-2 IgA neutralising antibody responses in convalescent plasma. *Clin Transl Immunology* 11: e1424.
36. Hennings V, Thörn K, Albinsson S, et al. (2022): The presence of serum anti-SARS-CoV-2 IgA appears to protect primary health care workers from COVID-19. *Eur J Immunol* 52: 800-809.
37. Jain R, Mallya MV, Amoncar S, et al. (2022): Seroprevalence of SARS-CoV-2 among potential convalescent plasma donors and analysis of their deferral pattern: Experience from tertiary care hospital in western India. *Transfus Clin Biol* 29: 60-64.
38. Steenhuis M, Mierlo G, Derksen NIL, et al. (2021): Dynamics of antibodies to SARS-CoV-2 in convalescent plasma donors. *Clin Transl Immunology* 10: e1285.
39. Rangel-Ramírez VV, Macías-Piña KA, Servin-Garrido RR, et al. (2022): A systematic review and meta-analysis of the IgA seroprevalence in COVID-19 patients: Is there a role for IgA in COVID-19 diagnosis or severity? *Microbiol Res* 263: 127105.
40. Kaneko Y, Sugiyama A, Tanaka T, et al. (2022): The serological diversity of serum IgG/IgA/IgM against SARS-CoV-2 nucleoprotein, spike, and receptor-binding domain and neutralizing antibodies in patients with COVID-19 in Japan. *Health Sci Rep* 5: e572.
41. Zervou FN, Louie P, Stachel A, et al. (2021): SARS-CoV-2 antibodies: IgA correlates with severity of disease in early COVID-19 infection. *J Med Virol* 93: 5409-5415.
42. Montaña Mendoza VM, Mendez Cortina YA, Rodríguez-Perea AL, et al. (2023): Biological sex and age-related differences shape the antiviral response to SARS-CoV-2 infection. *Heliyon* 9: e13045.
43. Tsvetava L, Chitadze N, Chanturia G, et al. (2022): Antibody profiling reveals gender differences in response to SARS-CoV-2 infection. *AIMS Allergy Immunol* 6: 6-13.
44. Wagner A, Garner-Spitzer E, Jasinska J, et al. (2018): Age-related differences in humoral and cellular immune responses after primary immunisation: indications for stratified vaccination schedules. *Sci Rep* 8: 9825.
45. Brockman MA, Mwimanzzi F, Lapointe HR, et al. (2022): Reduced magnitude and durability of humoral immune responses to COVID-19 mRNA vaccines among older adults. *J Infect Dis* 225: 1129-1140.
46. Williams KV, Moehling Geffel K, Alcorn JF, et al. (2023): Factors associated with humoral immune response in older adults who received egg-free influenza vaccine. *Vaccine* 41: 862-869.
47. Buckley CE III, Dorsey FC (1970): The effect of aging on human serum immunoglobulin concentrations. *J Immunol* 105: 964-972.
48. Challacombe SJ, Percival RS, Marsh PD (1995): Age-related changes in immunoglobulin isotypes in whole and parotid saliva and serum in healthy individuals. *Oral Microbiol Immunol* 10: 202-207.
49. Crisp HC, Quinn JM (2009): Quantitative immunoglobulins in adulthood. *Allergy Asthma Proc* 30: 649-654.
50. Lorent D, Nowak R, Roxo C, et al. (2021): Prevalence of anti-SARS-CoV-2 antibodies in Poznań, Poland, after the first wave of the COVID-19 pandemic. *Vaccines (Basel)* 9: 541.
51. Zejda JE, Brożek GM, Kowalska M, et al. (2021): Seroprevalence of anti-SARS-CoV-2 antibodies in a random sample of inhabitants of the Katowice Region, Poland. *Int J Environ Res Public Health* 18: 3188.
52. World Health Organization. One year since the emergence of COVID-19 virus variant Omicron [Internet] (2022). Available from: <https://www.who.int/news-room/feature-stories/detail/one-year-since-the-emergence-of-omicron> (cited 2023 Dec 10).
53. Rzymiski P, Pokorska-Śpiwak M, Jackowska T, et al. (2023): Key considerations during the transition from the acute phase of the COVID-19 pandemic: A narrative review. *Vaccines* 11: 1502.